radiation syndrome


Also found in: Dictionary, Medical, Encyclopedia, Wikipedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for radiation syndrome

syndrome resulting from exposure to ionizing radiation (e.g., exposure to radioactive chemicals or to nuclear explosions)

References in periodicals archive ?
Immediately after exposure, the most critical components of acute radiation syndrome are the hematopoietic (bone marrow) and early-onset gastrointestinal (GI) syndromes because symptoms begin very quickly and can be lethal.
The contract is for the advanced preclinical development of OrbeShield (oral beclomethasone 17,21-dipropionate or oral BDP) as a MCM for the treatment of gastrointestinal acute radiation syndrome (GI ARS).
7 million for our ricin toxin vaccine (RiVax(TM)) program utilizing our ThermoVax(TM) vaccine thermostablization platform, and adds to government contracts previously awarded for OrbeShield(TM) in gastrointestinal acute radiation syndrome (GI ARS) of up to $32.
6 million contract to Harvard University s Wyss Institute for Biologically Inspired Engineering to apply its breakthrough organs-on-chips technology to assess medical countermeasures for treating acute radiation syndrome (ARS), also known as radiation sickness.
4 million under an option exercised by the Biomedical Advanced Research and Development Authority (BARDA) in the Office of the Assistant Secretary for Preparedness and Response of the Department of Health and Human Services, for the advanced development of CLT-008, a first-in-class, allogeneic, cell-based therapy for the treatment of Acute Radiation Syndrome (ARS).
The company's pipeline of products are in development with a potential to treat a wide range of conditions including blood cancers, non-malignant hematological diseases such as sickle cell disease and thalassemia, neutropenia and acute radiation syndrome, autoimmune diseases, solid tumors and genetic metabolic diseases as well as conditions that can be helped by adaptive immune therapy such as solid and blood cancers refractory to chemotherapy.
The company s pipeline of stem cell therapy products are in development to treat a wide range of conditions including blood cancers, solid tumors, non-malignant hematological diseases such as hemoglobinopathies, neutropenia and acute radiation syndrome, autoimmune diseases and metabolic diseases as well as conditions that can be helped by regenerative medicine.
This includes the gastrointestinal acute radiation syndrome program which is funded by both the National Institute of Allergy and Infectious Diseases (NIAID; up to $6.
will also be presenting Poster #1144 titled "Ex vivo-Generated Mouse Myeloid Progenitor Cells Mitigate Gastrointestinal Acute Radiation Syndrome when Administered up to 5 Days after Irradiation.
8 million primarily related to contracts with the US Department of Health and Human Service's Biomedical Advanced Research and Development Authority (BARDA) and the National Institute of Allergy and Infectious Diseases (NIAID) in support of OrbeShield(TM) (oral beclomethasone 17,21-dipropionate or BDP) development in the treatment of gastrointestinal acute radiation syndrome (GI ARS).
The study, published on May 4, 2012 in the scientific journal, Radiation Research, represents the first report of an effective radiation countermeasure for Acute Radiation Syndrome (ARS) across a broad range of lethal radiation doses when administered as late as seven (7) days after irradiation.
Avaxia's program to develop a treatment agent for GI acute radiation syndrome is supported by a contract from the Biomedical Advanced Research and Development Authority (BARDA).
The company's pipeline of stem cell therapy products are in development to treat a wide range of conditions including blood cancers such as leukemia and lymphoma, solid tumors, non-malignant hematological diseases such as hemoglobinopathies, acute radiation syndrome, autoimmune diseases and metabolic diseases as well as conditions that can be helped by regenerative medicine.
The contract is for the advanced preclinical development of OrbeShield(TM) (oral beclomethasone 17,21-dipropionate or oral BDP) as a MCM for the treatment of gastrointestinal acute radiation syndrome (GI ARS).
Nasdaq:MAXY) today announced that it has been advised by the Biomedical Advanced Research and Development Authority (BARDA) that Maxygen's proposal for the development of its MAXY-G34 product candidate as a potential medical countermeasure for Acute Radiation Syndrome (ARS) will not be considered for a contract award.